复宏汉霖:PD-L1 ADC再获临床突破,末线食管癌疗效优异

医药笔记
Jan 10

▎Armstrong2026年1月8-10日,2026年ASCO GI会议即将在美国加利福尼亚州旧金山举办。1月5日,常规会议摘要正式公开。复宏汉霖PD-L1 ADC新药HLX43治疗复发或转移性食管鳞癌的二期临床数据首度在此次会议上披露。截至2025年11月25日,该二期临床共计入组37例患者,2mg/kg、2.5mg/kg、3.0mg/kg剂量组分别入组12例、12例、13例患者。86.5%的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10